Redesigning Cell Therapy: How ET501 Targets High-Risk Neuroblastoma

ATLANTA, GA – October 15, 2026 — The sympathetic nervous system, a complex network responsible for our "fight or flight" responses, is the battleground for one of the most formidable pediatric cancers: neuroblastoma. Every year, physicians in the United States diagnose more than 650 cases, typically in children at a median age of just 17 months. For those facing high-risk variants of the disease, the prognosis has historically been grim. According to comprehensive data from the Children's Oncology Group analyzing nearly 5,000 patients over a decade, the five-year event-free survival rate hovers at a mere 51.2%, with overall survival at 62.5%.

These numbers represent more than just clinical statistics; they are a stark reminder of the urgent need for therapeutic innovation in pediatric oncology. Traditional modalities—intensive chemotherapy, radiation, and even early-generation immunotherapies—often fall short against the aggressive, resilient nature of solid tumors. However, a recent development from a clinical-stage gene and cell therapy company suggests a new paradigm may be on the horizon.

Expression Therapeutics, Inc. announced today that it has been awarded a $2,058,885 Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI). The two-year funding initiative is specifically earmarked to advance ET501, an investigational PTK7-targeted gamma delta (γδ) T-cell therapy, toward an Investigational New Drug (IND) application with the U.S. Food and Drug Administration.

Engineering the In Situ Drug Factory

To understand the potential of ET501, one must look closely at the biological architecture of the therapy. Traditional CAR-T cell therapies, which have revolutionized the treatment of blood cancers like leukemia and lymphoma, often struggle against solid tumors. Solid malignancies construct hostile, immunosuppressive microenvironments that actively repel or exhaust engineered immune cells. Furthermore, systemic administration of therapies designed to activate the immune system can lead to severe, sometimes fatal, side effects like cytokine release syndrome.

The Georgia-based biotech is attempting to bypass these hurdles using its proprietary ADEPT-STAR platform. Rather than relying solely on the direct killing capacity of the engineered cells, the platform transforms them into localized delivery vehicles—essentially, in situ drug factories.

Using the company's LENTeT lentiviral delivery system, γδ T cells are engineered to secrete a specific T-cell engager directly at the tumor site. ET501 is designed to produce a PTK7×CD3 bispecific engager. One end of this molecular bridge binds to PTK7 (protein tyrosine kinase 7), a protein heavily overexpressed on the surface of neuroblastoma cells. The other end binds to CD3, a receptor found on all T cells.

"ET501 is designed to have γδ T cells produce a PTK7-directed engager inside the tumor, where it can recruit the immune cells already present," explained Brian Petrich, Ph.D., Vice President of Research and Development at Expression Therapeutics and the Contact Principal Investigator on the SBIR award. "This grant funds the studies that will show whether that design performs as intended and whether it supports an IND application."

By secreting the engager directly within the tumor microenvironment, the therapy theoretically directs both the infused γδ T cells and the patient's own naturally occurring T cells to attack the cancer. This localized activation is a critical innovation, aiming to maximize tumor destruction while minimizing the systemic toxicity that plagues broad-spectrum immunotherapies. Antigen escape—a phenomenon where tumor cells mutate to stop expressing the targeted protein, rendering the therapy useless—is a persistent threat in single-target treatments. By recruiting endogenous immune cells that can recognize a variety of tumor antigens, the bispecific engager approach may create a broader, more durable immune response against the tumor.

Bypassing the GD2 Bottleneck

The current competitive landscape for high-risk neuroblastoma treatments is heavily focused on a different target: GD2. Monoclonal antibodies targeting this disialoganglioside, such as dinutuximab and naxitamab, have become mainstays in the standard of care and have demonstrably improved survival rates. Additionally, several prominent research institutions are currently running clinical trials for GD2-targeted CAR-T therapies.

However, targeting GD2 comes with significant clinical baggage. Because GD2 is also expressed on peripheral nerves, therapies targeting it often induce severe, dose-limiting neuropathic pain, requiring heavy pain management protocols for young patients.

By pivoting to PTK7, ET501 explores an alternative pathway. PTK7 is highly implicated in the migration, invasion, and survival of neuroblastoma cells, making it an attractive target. While it is expressed at low levels in some normal tissues, the localized secretion mechanism of the ADEPT-STAR platform is specifically designed to mitigate off-tumor, on-target toxicities.

Furthermore, the foundational use of γδ T cells offers a distinct logistical and biological advantage. Unlike conventional alpha beta T cells, γδ T cells recognize stressed and cancerous cells without requiring a human leukocyte antigen (HLA) tissue match. In the realm of cell therapy, this is a massive differentiator. It opens the door for allogeneic, or "off-the-shelf," treatments. Using cells from healthy donors without the risk of graft-versus-host disease (GvHD) could drastically reduce manufacturing times and costs, ensuring therapies reach critically ill children faster than autologous therapies, which require engineering the patient's own compromised cells.

The Bridge to the Clinic

In the biotechnology sector, the journey from a promising preclinical concept to human trials is often referred to as the "valley of death." The financial burden of conducting the rigorous toxicology, pharmacology, and manufacturing studies required by the FDA for an IND application routinely stalls innovative therapies.

This is where federal funding mechanisms like the NCI SBIR program play a pivotal role. By injecting non-dilutive capital into early-stage companies, the government de-risks the science, allowing drug developers to bridge the gap between academic theory and clinical reality without sacrificing equity or bowing to premature commercial pressures.

"Children with high-risk neuroblastoma need treatment options beyond today's regimens," noted David Townson, Ph.D., Chief Executive Officer of Expression Therapeutics. "This award funds the work that stands between ET501 and an IND application. It also advances the second program on our γδ T-cell platform, ET401 for adults with neuroendocrine tumors."

The successful translation of ET501 will also hinge heavily on manufacturing capabilities—a frequent bottleneck in the cell therapy space. The drug developer holds a distinct advantage here, operating an internal 43,000-square-foot cGMP cell and viral vector manufacturing facility in Cincinnati, Ohio. In-house control over Chemistry, Manufacturing, and Controls (CMC) is increasingly recognized by industry analysts as a critical factor for regulatory success. It allows for rapid iteration, strict quality assurance, and the ability to seamlessly scale from preclinical batches to clinical-grade production.

The company's broader pipeline, which includes the lead program ET3 for hemophilia A—a candidate that has already completed a Phase 1 trial and secured FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations—demonstrates an established track record of navigating complex regulatory pathways. This institutional experience will be invaluable as ET501 approaches the IND threshold.

The development of ET501 represents more than just a single drug candidate; it is a convergence of advanced genetic engineering, novel biological targets, and strategic manufacturing infrastructure. As this therapy moves through the final stages of its preclinical evaluation, it carries the potential to fundamentally reshape how oncologists approach solid tumors, offering a glimpse into a future where cellular therapies are not only more precise but fundamentally safer for the most vulnerable patients.